Correlation of Clinical Outcomes with the Prominent Indication of Transcatheter Paravalvular Leak Closure: A Multicenter Experience.
aortic valve
heart failure
hemolysis
mitral valve
paravalvular leak
transcatheter closure
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
14 Jun 2023
14 Jun 2023
Historique:
received:
22
03
2023
revised:
07
05
2023
accepted:
08
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
A paravalvular leak (PVL) is a complication following valve replacement, which may lead to heart failure and hemolysis. The aim of this study is to investigate whether the clinical outcome after transcatheter PVL closure differs according to the prominent indication of the procedure (symptoms of heart failure or hemolysis). The data of consecutive patients who had transcatheter treatment for PVL between July 2011 and September 2022 in five Greek centers were analyzed. The primary endpoint was the technical, and clinical success rates with regards to the prominent indication of paravalvular leak closure. The secondary endpoints included the evaluation and comparison of the clinical and technical success in relation to the type of valve that was treated (aortic or mitral) as well as the survival analysis in relation to the closure indication and type of valve that was treated. In total, 60 patients were retrospectively studied (39% men, mean age 69.5 ± 11 years). Regarding the primary outcomes, the technical success in patients mainly suffering from hemolysis was 86.1%, while in those presenting heart failure it was 95.8%, Transcatheter paravalvular leak closure can be performed with high technical and clinical success rates without any difference according to the prominent indication of closure.
Sections du résumé
BACKGROUND
BACKGROUND
A paravalvular leak (PVL) is a complication following valve replacement, which may lead to heart failure and hemolysis. The aim of this study is to investigate whether the clinical outcome after transcatheter PVL closure differs according to the prominent indication of the procedure (symptoms of heart failure or hemolysis).
METHODS
METHODS
The data of consecutive patients who had transcatheter treatment for PVL between July 2011 and September 2022 in five Greek centers were analyzed. The primary endpoint was the technical, and clinical success rates with regards to the prominent indication of paravalvular leak closure. The secondary endpoints included the evaluation and comparison of the clinical and technical success in relation to the type of valve that was treated (aortic or mitral) as well as the survival analysis in relation to the closure indication and type of valve that was treated.
RESULTS
RESULTS
In total, 60 patients were retrospectively studied (39% men, mean age 69.5 ± 11 years). Regarding the primary outcomes, the technical success in patients mainly suffering from hemolysis was 86.1%, while in those presenting heart failure it was 95.8%,
CONCLUSIONS
CONCLUSIONS
Transcatheter paravalvular leak closure can be performed with high technical and clinical success rates without any difference according to the prominent indication of closure.
Identifiants
pubmed: 37373740
pii: jcm12124047
doi: 10.3390/jcm12124047
pmc: PMC10299245
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Expert Rev Med Devices. 2018 Sep;15(9):653-663
pubmed: 30129782
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
J Am Coll Cardiol. 2017 Apr 25;69(16):2067-2087
pubmed: 28427582
Hellenic J Cardiol. 2018 Nov - Dec;59(6):367-369
pubmed: 29366774
EuroIntervention. 2017 Mar 20;12(16):1962-1968
pubmed: 27973334
EuroIntervention. 2016 Feb;11(10):1195-200
pubmed: 26897292
JACC Cardiovasc Interv. 2016 Dec 12;9(23):2416-2426
pubmed: 27931593
JACC Cardiovasc Interv. 2017 Oct 9;10(19):1946-1956
pubmed: 28982558
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Eur Heart J Cardiovasc Imaging. 2016 Aug;17(8):835-835af
pubmed: 27311822
Thorac Cardiovasc Surg. 2020 Mar;68(2):148-157
pubmed: 29739021
Nat Rev Cardiol. 2019 May;16(5):275-285
pubmed: 30659248
EuroIntervention. 2020 Feb 20;15(14):1251-1259
pubmed: 31422926
Circ Cardiovasc Interv. 2017 Dec;10(12):
pubmed: 29246914
J Am Coll Cardiol. 2011 Nov 15;58(21):2210-7
pubmed: 22078427
Hellenic J Cardiol. 2021 Nov-Dec;62(6):416-422
pubmed: 33617960
Circ Cardiovasc Interv. 2022 Oct;15(10):e012193
pubmed: 36256693
Circulation. 2016 Sep 27;134(13):934-44
pubmed: 27587432
J Am Coll Cardiol. 2012 Apr 3;59(14):1275-86
pubmed: 22365424
J Am Coll Cardiol. 1992 Nov 15;20(6):1371-7
pubmed: 1385506
J Am Coll Cardiol. 2017 Jul 11;70(2):252-289
pubmed: 28315732